Grant: Project Grant - Priority Announcement: Patient-Oriented Research
University of Calgary
$100,000.00
High dose psilocybin-assisted therapy (PAT) for demoralization syndrome (DS) in people living with advanced cancer (PAC): A multi-site, randomized, controlled, double-blind, mixed-methods trial
EF 2023-24
Résumé
People living with advanced cancer often struggle with feelings of loss of hope and meaning in life, low mood, feelings of disheartenment, helplessness, and a sense of failure (demoralization), along with anxiety about end of life and fear of death; all of which can compromise overall quality of life and worsen their final months.
While some psychotherapies have been developed to help people cope with these symptoms, they are not always effective, quick or long-lasting. Similarly, the usual drug treatments may include antidepressant and antianxiety medicines, but these need to be taken daily, and are not always effective.
In combination with supportive psychotherapy, the psychedelic drug psilocybin (from magic mushrooms) has had promising results as a fast-acting and long-lasting treatment in small trials conducted in the United States to date. This has caused considerable excitement among people with cancer about the potential of just one or two doses of psilocybin to relieve these symptoms quickly, and for a prolonged period of time. Unfortunately, many people are now seeking out psilocybin therapy or other psychedelic treatments from relatively untrained therapists in the community, when we do not yet know if they are effective.
In this study we will investigate the impact of a single, high-dose of psilocybin along with meaning-focused supportive mindfulness therapy to 120 people with advanced cancer suffering demoralization, in a multi-site trial across Canada.
To do so we will train a group of publicly-funded therapists, who will then be in place at cancer centres across Canada to continue offering the therapy, should it prove effective. We will also engage administrative policy makers in these cancer centres and Health Canada, to further facilitate future implementation.
Throughout the study, we will employ best practice principles of equity, diversity and inclusion in composing our study team, choosing therapists and recruiting patient participants.
Programme
Project Grant - Priority Announcement: Patient-Oriented Research
Bénéficiaire
Emplacement
Alberta, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
494333
Name
Carlson Linda E
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Clinical
Prcname2
Randomized Controlled Trials 2
Projecttitle
High dose psilocybin-assisted therapy (PAT) for demoralization syndrome (DS) in people living with advanced cancer (PAC): A multi-site, randomized, controlled, double-blind, mixed-methods trial
Programtype2
Operating Grants
Orgnameinp2
University of Calgary
Cihramount2
$100,000
Cihrequipment2
$0
Programname2
Project Grant - Priority Announcement: Patient-Oriented Research
Keyworddelim
Advanced Cancer; Anxiety; Demoralization; Depression; Mindfulness-Based Intervention; Palliative Care; Psilocybin Assisted Therapy; Psychedelics; Psychosocial Oncology; Randomized Controlled Trial
Abstract
People living with advanced cancer often struggle with feelings of loss of hope and meaning in life, low mood, feelings of disheartenment, helplessness, and a sense of failure (demoralization), along with anxiety about end of life and fear of death; all of which can compromise overall quality of life and worsen their final months.
While some psychotherapies have been developed to help people cope with these symptoms, they are not always effective, quick or long-lasting. Similarly, the usual drug treatments may include antidepressant and antianxiety medicines, but these need to be taken daily, and are not always effective.
In combination with supportive psychotherapy, the psychedelic drug psilocybin (from magic mushrooms) has had promising results as a fast-acting and long-lasting treatment in small trials conducted in the United States to date. This has caused considerable excitement among people with cancer about the potential of just one or two doses of psilocybin to relieve these symptoms quickly, and for a prolonged period of time. Unfortunately, many people are now seeking out psilocybin therapy or other psychedelic treatments from relatively untrained therapists in the community, when we do not yet know if they are effective.
In this study we will investigate the impact of a single, high-dose of psilocybin along with meaning-focused supportive mindfulness therapy to 120 people with advanced cancer suffering demoralization, in a multi-site trial across Canada.
To do so we will train a group of publicly-funded therapists, who will then be in place at cancer centres across Canada to continue offering the therapy, should it prove effective. We will also engage administrative policy makers in these cancer centres and Health Canada, to further facilitate future implementation.
Throughout the study, we will employ best practice principles of equity, diversity and inclusion in composing our study team, choosing therapists and recruiting patient participants.
Competitiondate
202309
Approvedterm2
1 yr 0 mth
Pinamesdelim
Carlson, Linda E; Richardson, Harriet
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $100,000~ $0~